Fujifilm India enhancing disease management and prognosis of Covid-19 with its revolutionary screening solutions
- FUJI DRI-CHEM brings healthcare professionals a new world of Clinical Chemistry - With its Dri Chemistry solution, the company can facilitate LDH and CRP testing only in 6 minutes Fujifilm India Private Limited, a pioneer in imaging and
– FUJI DRI-CHEM brings healthcare professionals a new world of Clinical Chemistry
– With its Dri Chemistry solution, the company can facilitate LDH and CRP testing only in 6 minutes
Fujifilm India Private Limited, a pioneer in imaging and healthcare technologies, in line with its commitment to provide aid for the unprecedented crisis, has been strengthening its pledge to contribute to healthcare experts with the help of its progressive Dri Chemistry solutions that can aid LDH and CRP testing in just 6 minutes.
The increasing outbreak of COVID-19 cases is putting high pressure on healthcare services worldwide. At this stage, fast, accurate and early clinical assessment of the disease severity is vital. Combatting the pandemic, one of the main obstacles when it comes to discovering reliable solutions for the disease caused by SARS-CoV-2, are the new and alarming developments about the virus that continue to increase the anxiety that has been created around the disease.
Another such troubling factor of concern has to be able to scale the severity of the disease. Not only was it initially uncertain who are the individuals who fall into the high-risk category of severe COVID-19, but even the lack or presence of severe symptoms of COVID-19 in people of similar age, complications, and other factors also indicated that there may not be any specific parameter to determine this.
Recent research suggests that relatively high levels of LDH alone seem to play a crucial role in distinguishing the vast majority of cases that require immediate medical attention. This finding is consistent with current medical knowledge that high LDH levels are associated with tissue breakdown occurring in various diseases, including pulmonary disorders such as pneumonia. The use of the biomarkers suggests a simple and operable decision rule to quickly predict patients at the highest risk, allowing them to be prioritized and potentially reducing the mortality rate.
With Fujifilm’s dry chemistry analyzer, healthcare professionals can perform multiple test parameters of Clinical Chemistry. It has a built-in auto-pipetting system, requires no calibration and no water, providing easy preparation and maintenance. The new FUJI DRI-CHEM NX500i and NX700i deliver results using a simple 3-step procedure. With its quick, easy operation and compactness, “Real Time and Borderless” Clinical Chemistry has now been made possible.
Commenting on this, Mr. Chander Shekhar Sibal, Senior Vice President, Fujifilm India said, “As India battles the highest number of coronavirus cases each day, Fujifilm is committed to support the healthcare professionals with our advanced technological solutions. Our cutting-edge Dri Chem technological solutions can help doctors decide how actively they need to handle patients, track their discharge and other clinical decisions. At Fujifilm, we believe it’s time for all of us to come together and protect the humanity by acting responsibly and by doing what we can do to prevent further spread of COVID-19.”
With Fujifilm’s dry chemistry solutions helping in conducting the prognosis within just 6 minutes, the company is aiding doctors in a quick analysis of the patients. The clinical chemistry solutions delivers fine chemical technology which is Japanese patented technology for manufacturing of Dri Chemistry Slides. The slides ensure ease of work and no trained technicians are required to use the medical solutions. Further with plug and play equipment, the NX500i can run upto 128 tests per hour and the NX700i can run upto 190 tests per hour respectively.